Orexo ABShs Aktie
| 2,48EUR | 0,02EUR | 0,61% |
WKN: A0HG6G / ISIN: SE0000736415
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 138 | 121 | 126 | 116 | 110 |
| Umsatz pro Mitarbeiter in Mio. EUR | 4,81 | 4,67 | 4,95 | 5,51 | 5,36 |
Bilanz (in Mio. SEK) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 832 | 866 | 736 | 459 | 446 |
| Summe Anlagevermögen | 401 | 408 | 374 | 328 | 148 |
| Summe Aktiva | 1 233 | 1 274 | 1 109 | 787 | 595 |
Bilanz (in Mio. SEK) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 674 | 924 | 915 | 728 | 721 |
| Summe Eigenkapital | 559 | 350 | 194 | 59 | -126 |
| Summe Passiva | 1 233 | 1 274 | 1 109 | 787 | 595 |
Adresse
| Virdings allé 32 A, 754 50 Uppsala | |
| Telefon | +46 (18) 780-88-00 |
| Internet | http://www.orexo.se |
Management
|
Cecilia Coupland
Vice President & Head-Operations |
|
Christine Rankin
Independent Director |
|
Edward Kim
Chief Medical Officer |
|
Fredrik Järrsten
Chief Financial Officer & Executive Vice President |
|
Friedrich von Bohlen und Halbach
Chairman |
|
George Frederick Wilkinson
Independent Director |
|
Jonas Savmarker
Scientific Director |
|
Lena Wange
Manager-Communications & Investor Relations |
|
Nikolaj Sørensen
President & Chief Executive Officer |
|
Robert Rönn
SVP & Head-Research & Development |
|
Robin Evers
Independent Director |
|
Staffan Lindstrand
Independent Director |